Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the …
Background Microvascular and macrovascular thrombotic events are among the hallmarks
of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is …
of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is …
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the …
B Bikdeli, AH Talasaz, F Rashidi… - Thrombosis …, 2020 - europepmc.org
Background Microvascular and macrovascular thrombotic events are among the hallmarks
of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is …
of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is …
[PDF][PDF] Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design …
Thrombosis Research, 2020 - academia.edu
Background: Microvascular and macrovascular thrombotic events are among the hallmarks
of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is …
of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is …
[HTML][HTML] Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and …
B Bikdeli, AH Talasaz, F Rashidi… - Thrombosis …, 2020 - ncbi.nlm.nih.gov
Background Microvascular and macrovascular thrombotic events are among the hallmarks
of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is …
of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is …
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the …
B Bikdeli, AH Talasaz, F Rashidi… - Thrombosis …, 2020 - thrombosisresearch.com
Background Microvascular and macrovascular thrombotic events are among the hallmarks
of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is …
of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is …
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the …
B Bikdeli, AH Talasaz, F Rashidi… - Thrombosis …, 2020 - vbn.aau.dk
Background: Microvascular and macrovascular thrombotic events are among the hallmarks
of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is …
of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is …
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the …
B Bikdeli, AH Talasaz, F Rashidi… - Thrombosis …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Microvascular and macrovascular thrombotic events are among the hallmarks
of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is …
of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is …
[引用][C] Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design …
B Bikdeli, AH Talasaz, F Rashidi… - Thrombosis …, 2020 - portalcientifico.uah.es
Background: Microvascular and macrovascular thrombotic events are among the hallmarks
of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is …
of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is …
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: rationale and design of the …
B Bikdeli, AH Talasaz, F Rashidi, B Sharif-Kashani… - 2020 - cabidigitallibrary.org
Background: Microvascular and macrovascular thrombotic events are among the hallmarks
of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is …
of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is …
[PDF][PDF] Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design …
Thrombosis Research, 2020 - academia.edu
Background: Microvascular and macrovascular thrombotic events are among the hallmarks
of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is …
of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is …